Vamsidhar Velcheti, MD, FACP

Vamsidhar Velcheti, MD, discusses the importance of real-world data for patients with non–small cell lung cancer.

An epigenetic strategy under study at Cleveland Clinic combines THU, a cytidine deaminase inhibitor, with decitabine and nivolumab (Opdivo) in patients with non-small cell lung cancer. The results of early studies demonstrate that THU may help prime the immune system.